首页 | 本学科首页   官方微博 | 高级检索  
检索        

利奈唑胺对临床分离阳性球菌的体外敏感性分析
引用本文:肖秀美,刘振英,张晓伟,张捷.利奈唑胺对临床分离阳性球菌的体外敏感性分析[J].中国临床药理学与治疗学,2008,13(9).
作者姓名:肖秀美  刘振英  张晓伟  张捷
作者单位:北京大学第三医院检验科,北京,100191
摘    要:目的:对比利奈唑胺与万古霉素及其他几种常用抗菌药物对临床分离阳性球菌的体外抗菌活性。方法:按照NCCLS(CLSI)2007纸片扩散法操作标准测定利奈唑胺与其他几种常用抗菌药物的体外抗菌活性。结果:本院分离的耐甲氧西林金黄色葡萄球菌(MRSA)比例较高(79.1%),利奈唑胺、万古霉素、替考拉宁的敏感率均达到100%。耐甲氧西林凝固酶阴性葡萄球菌(MRC-NS)的比例较MRSA高(88.9%),利奈唑胺与万古霉素、替考拉宁活性相当,敏感率均为100%。利奈唑胺对粪肠球菌的活性与万古霉素、替考拉宁相当,对屎肠球菌的活性优于万古霉素和替考拉宁(100%,80.4%,78.1%),对青霉素耐药的肺炎链球菌(PRSP)也表现了优越的抗菌活性。结论:对于MRSA、MRCNS、PRSP、粪肠球菌,利奈唑胺与万古霉素、替考拉宁的活性相当,均为100%的敏感率;对屎肠球菌的抗菌活性优于万古霉素和替考拉宁,是治疗多药耐药阳性球菌感染的新型药物。

关 键 词:利奈唑胺  万古霉素  阳性球菌  多药耐药  敏感性  体外

Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro
XIAO Xiu-mei,LIU Zheng-ying,ZHANG Xiao-wei,ZHANG Jie.Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro[J].Chinese Journal of Clinical Pharmacology and Therapeutics,2008,13(9).
Authors:XIAO Xiu-mei  LIU Zheng-ying  ZHANG Xiao-wei  ZHANG Jie
Institution:XIAO Xiu-mei; LIU Zheng-ying; ZHANG Xiao-wei; ZHANG Jie Department of Laboratory Medicine; Third Hospital of Peking University; Beijing 100191; China;
Abstract:AIM: To compare the antibacterial activity of linezolid with vancomycin and other antibacterials against clinical gram-positive cocci isolates in vitro.METHODS: The antibacterial activity of linezolid and other antibacterials were determined according to the disk diffusion guidelines of NCCLS(CLSI) 2007 in vitro.RESULTS: The incidence of methicillin-resistant Staphylococcus aureus(MRSA) isolated in our hospital was 79.1%,linezolid showed great susceptibility as well as vancomycin and teicoplanin.The incidence of methicillin-resistant coagulase negative Staphylococcus(MRCNS,88.9%) was higher than that of MRSA,the antibacterial activity of linezolid was comparable with that of vancomycin and teicoplanin,and the sensitivity was 100%.The activity of linezolid against enterococcus faecalis is similar to that of vancomycin and teicoplanin,the activity of linezolid against enterococcus faecium is prior to that of vancomycin and teicoplanin(100%,80.4%,78.1%).Linezolid also showed great activity against penicillin resistant streptococcus pneumonia(PRSP).CONCLUSION: The antibacterial activity of linezolid was comparable with that of vancomycin and teicoplanin against MRSA,MRCNS,PRSP and enterococcus faecalis,and the sensitivity were all 100%.The antibacterial activity was better than those of the two drugs against enterococcus faecium in vitro.Linezolid could be a promising therapeutic option to treat infections caused by multi-resistant gram-positive cocci.
Keywords:linezolid  vancomycin  gram-positive cocci  multidrug resistance  sensitivity  in vitro
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号